Plain-English translation of NCT07565285 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining a new immune-boosting drug called with — a well-known immunotherapy — can help your body fight stage 3 melanoma more effectively before surgery. The study will give you the medication for about 9 weeks, then you'll have surgery to remove the melanoma, and your follow-up treatment will depend on how well your tumor responded.
Currently, even with existing treatments, some melanoma patients still experience cancer progression after surgery. This medication is being tested to see if boosting your immune system in a new way — combined with — can help prevent that from happening and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You will take the new medication by mouth for 9 weeks, following a pattern of 3 days on and 4 days off each week, while also receiving by intravenous infusion every 3 weeks. After this treatment period, you'll undergo surgery to remove the melanoma. Following surgery, your further treatment will depend on how well your tumor responded — some patients may simply be observed, while others may receive additional medication to reduce the risk of cancer return.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Australia